Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Corticosteroids vs placebo Limitations in participation at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | RR 0.83 [0.05, 12.77] | 1 study · 75 participants | Moderate |
Corticosteroids vs placebo 1Small sample size. · people with nerve damage (< 6 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Corticosteroids vs placebo Improvement in sensory nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | RR 0.97 [0.65, 1.45] | 1 study · 71 participants | Moderate |
Corticosteroids vs placebo Improvement in motor nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy Corticosteroids for treating nerve damage in leprosy (2016) · Cochrane | no estimate extracted | 1 study · 21 participants | Low |
Simple decompression vs transposition Proportion of participants with clinical improvement in function compared to baseline · people with ulnar neuropathy at the elbow Treatment for ulnar neuropathy at the elbow (2016) · Cochrane | RR 0.93 [0.8, 1.08] | 3 studies · 261 participants | Moderate |
Simple decompression vs transposition Subgroup: proportion of participants with clinical improvement in function compared to baseline ‐ simple decompression versus subcutaneous transposition · people with ulnar neuropathy at the elbow Treatment for ulnar neuropathy at the elbow (2016) · Cochrane | RR 0.92 [0.74, 1.14] | 1 study · 147 participants | Moderate |
Simple decompression vs transposition Subgroup: proportion of participants with clinical improvement in function compared to baseline ‐ simple decompression versus submuscular transposition · people with ulnar neuropathy at the elbow Treatment for ulnar neuropathy at the elbow (2016) · Cochrane | RR 0.95 [0.77, 1.17] | 2 studies · 114 participants | Moderate |
Simple decompression vs transposition Adverse events: proportion of participants with deep/superficial wound infections · people with ulnar neuropathy at the elbow Treatment for ulnar neuropathy at the elbow (2016) · Cochrane | RR 0.32 [0.12, 0.85] | 3 studies · 261 participants | Moderate |
Antioxidant vs placebo Ataxia rating score ICARS; range 0 to 100) · people with Friedreich ataxia Pharmacological treatments for Friedreich ataxia (2016) · Cochrane | no estimate extracted | 2 studies · 72 participants | Low |
Antioxidant vs placebo Ejection fraction · people with Friedreich ataxia Pharmacological treatments for Friedreich ataxia (2016) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Antioxidant vs placebo End‐diastolic interventricular septal thickness (IVSTd) Measured in mm · people with Friedreich ataxia Pharmacological treatments for Friedreich ataxia (2016) · Cochrane | no estimate extracted | 2 studies · 72 participants | Very low |
Antioxidant vs placebo Left ventricular mass (LVM) Measured in g · people with Friedreich ataxia Pharmacological treatments for Friedreich ataxia (2016) · Cochrane | no estimate extracted | 1 study · 28 participants | Low |
Antioxidant vs placebo Survival (not measured) · people with Friedreich ataxia Pharmacological treatments for Friedreich ataxia (2016) · Cochrane | no estimate extracted | NR | No studies |
Antioxidant vs placebo Severe adverse events · people with Friedreich ataxia Pharmacological treatments for Friedreich ataxia (2016) · Cochrane | RR 1 [0.07, 15] | 2 studies · 72 participants | Low |
Intravenous immunoglobulin vs placebo Change in muscle strength at 6 months (%) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 3 studies · 78 participants | Ungraded |
Interferon beta‐1a vs placebo Change in handgrip strength at 6 months (%) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 2 studies · 58 participants | Ungraded |
Interferon beta‐1a vs placebo Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Significant adverse events · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 2 studies · 58 participants | Ungraded |
Methotrexate vs placebo Change in muscle strength at 6 months (%) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 44 participants | Ungraded |
Methotrexate vs placebo Change in muscle strength at 12 months (%) ‐ MMT · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 44 participants | Moderate |
Methotrexate vs placebo Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Significant adverse events · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | RR 8.76 [1.19, 64.28] | 1 study · 44 participants | Moderate |
Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate Change in muscle strength at 6 months (%) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 11 participants | Ungraded |
Intravenous immunoglobulin vs placebo Change in muscle strength at 12 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate Change in muscle strength at 12 months (%) ‐ QMT · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 11 participants | Very low |
Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate Change in muscle mass at 12 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate Change in handgrip strength at 6 months (%) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 11 participants | Ungraded |
Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate Significant adverse events · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 11 participants | Ungraded |
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Change in muscle strength at 6 months (%) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 11 participants | Ungraded |
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Change in muscle strength at 12 months (%) (using MMT or QMT) at 12 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs placebo Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Significant adverse events · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 11 participants | Ungraded |
Oxandrolone vs placebo Change in muscle strength at 6 months (%) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 16 participants | Ungraded |
Oxandrolone vs placebo Change in muscle strength at 12 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Oxandrolone vs placebo Change in muscle mass at 6 months (%) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 1 study · 16 participants | Ungraded |
Oxandrolone vs placebo Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Oxandrolone vs placebo Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Oxandrolone vs placebo Significant adverse events · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs placebo Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs placebo Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs placebo Significant adverse events · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 3 studies · 78 participants | Ungraded |
Interferon beta‐1a vs placebo Change in muscle strength at 6 months (normalised MMT score ‐ see Characteristics of Studies table) · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | 2 studies · 58 participants | Moderate |
Interferon beta‐1a vs placebo Change in muscle strength at 12 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |